GRAIL, Inc.

FRC's fair value estimate for GRAIL, Inc., and the rating behind it. GRAL last traded at $139.91; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for GRAIL, Inc.. Starting points for GRAIL, Inc.: EPS -$9.08, beta 3.25 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for GRAIL, Inc.. GRAIL, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for GRAIL, Inc.. Trailing twelve-month EPS for GRAIL, Inc. stands at -$9.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for GRAIL, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

GRAIL, Inc. valued side by side against its closest peers. GRAIL, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold GRAIL, Inc., and how their positions are changing. At a $6.25B market value, institutional positions materially move GRAIL, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by GRAIL, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming GRAIL, Inc.. GRAIL, Inc. is a $6.25B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming GRAIL, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for GRAIL, Inc.. Coverage tracks GRAIL, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.